23andMe Research Institute closes $305M buy of 23andMe assets after Regeneron $256M bid (July 2025)
TTAM Research Institute — now operating as 23andMe Research InstituteDealroom has a profile for this one. Try Dealroom →, a California nonprofit founded and led by Anne WojcickiDealroom has a profile for this one. Try Dealroom → — completed the acquisition of substantially all of 23andMe Holding Co.'s Personal Genome Service and Research Services assets for $305 million in cash on July 14, 2025, under a court-supervised Chapter 11 sale. The purchase excluded Lemonaid HealthDealroom has a profile for this one. Try Dealroom →, which TTAM agreed to sponsor separately for $2.5 million.
Since the July 2025 close, the deal has kept 23andMe's consumer genetics and research operations running under a nonprofit medical research institute rather than a public company. Customers keep DNA testing and research participation options, including the ability to change whether their data is used in research. The Institute is distinct from the legacy 23andMe Holding Co. bankruptcy estate.
23andMe had filed for Chapter 11 in March 2025 after a sharp decline from its SPAC-era valuation. A bankruptcy auction in mid-May 2025 named Regeneron Pharmaceuticals the successful bidder at $256 million for substantially all assets. Bidding was later reopened; Regeneron declined to raise its offer, and TTAM closed at $305 million in July 2025.
- Regeneron's May 2025 auction win: $256M
- TTAM's July 2025 closed purchase price: $305M cash, plus assumed liabilities and cure costs
- Separate Lemonaid carve-out: $2.5M
- 23andMe SPAC-era deal valuation (2021): about $3.5B
As of the July 2025 closing, Chapter 11 cases remained pending, with distributions to creditors still to be sorted. Privacy of genetic data was a central concern throughout the 2025 sale process; the buyer pledged continued choice and transparency for customers.
A once-$3.5B SPAC-era genetics brand exited bankruptcy in 2025 as a nonprofit-controlled consumer and research platform — a sharp step-down from public-market highs, and a reminder that Regeneron's $256 million bid was not the final price.
Read more: Regeneron · CNBC · SEC 8-K · SEC Ex-99.1 · 23andMe Research Institute
Image: 23andMe headquarters, Brisbane, California. Credit: Coolcaesar / Wikimedia Commons (CC BY-SA 4.0).